Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2019-02-05 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically mentions an 'Other Events' section where the company announces that the FDA granted Orphan Drug Status for a drug candidate. It also includes a press release as an exhibit. The document is short (3063 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing types. It does not contain financial statements or detailed management discussion. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2019-02-05 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 15, 2019, for Moleculin Biotech, Inc. The key content is Item 7.01 Regulation FD Disclosure, which states that the company will use the presentation set forth as Exhibit 99.1 in meetings with the investment community. The exhibit is described as an "Investor Presentation dated January 14, 2019." There are no financial statements or detailed financial data included in the text, only a reference to the investor presentation. The document is relatively short (3638 characters) and primarily serves to announce and furnish the investor presentation rather than being the presentation itself or a detailed financial report. According to the classification rules, this type of document is best classified as an Investor Presentation (IP).
2019-01-15 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 7, 2019, for Moleculin Biotech, Inc. It includes a Regulation FD Disclosure indicating that the company will use the attached presentation (Exhibit 99.1) in meetings with the investment community. The document explicitly states that the information is being furnished and not filed, and the main content is an investor presentation. The document length is 3520 characters, which is relatively short and primarily serves as an announcement and attachment of the investor presentation rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP).
2019-01-07 English
SABBY 13G-A MBRX 1.03.19
Major Shareholding Notification
2019-01-03 English
8-K
Call Transcript Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 12, 2018. It specifically mentions that the company held a live conference call on that date and is furnishing the conference call script as Exhibit 99.1. The text states that the exhibit is a conference call script, which aligns with a transcript or script of a company conference call. There is no indication of financial statements or detailed financial data, so it is not an earnings release or interim report. The document is not an announcement of a report publication but the actual script of a call. Therefore, the most appropriate classification is Call Transcript (CT). The document length is 3397 characters, which is consistent with a transcript or script rather than a full report.
2018-12-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated November 13, 2018, from Moleculin Biotech, Inc. It announces the issuance of a press release containing financial results for the quarter ended September 30, 2018. The text explicitly states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a notification of the earnings release. Given the document length is 3063 characters, which is relatively short and mainly an announcement, it fits the criteria for an Earnings Release (ER) announcement. The document is not the full earnings release but a Form 8-K filing announcing it. However, since the filing is a Form 8-K announcing the earnings release, and the content is primarily about the earnings results announcement, the best classification is Earnings Release (ER).
2018-11-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.